Comparative Pharmacology
Head-to-head clinical analysis: NORINYL 1 50 28 DAY versus NORLESTRIN 28 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL 1 50 28 DAY versus NORLESTRIN 28 1 50.
NORINYL 1+50 28-DAY vs NORLESTRIN 28 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive